Albeit early, anti-CD19 CAR NK (natural killer)-cells derived from cord blood have shown efficacy in patients with relapsed/refractory non-Hodgkin’s lymphoma or CLL without cytokine release syndrome, neurotoxicity, or graft-versus-host disease92. The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.